MATINAS BIOPHARMA HOLDINGS, INC. Marketable Securities, Unrealized Gain (Loss)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Marketable Securities, Unrealized Gain (Loss) of $229.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-05-10
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $229.00K, a 52.69% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was -$111.00K, a 177.08% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was $181.00K, a 241.51% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was $125.00K, a 47.06% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2022 was $679.00K, a 81.55% increase from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was $374.00K, a 57.14% increase from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2020 was $238.00K, a 23700.00% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2019 was $1.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 3 month as first filed | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-03-31 | $229.00K 10-Q · filed 2023-05-10 | $118.00K derived: sum of 2 quarters · filed 2023-05-10 | $299.00K derived: sum of 3 quarters · filed 2023-05-10 | $424.00K derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2022-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $70.00K derived: sum of 2 quarters · filed 2023-03-15 | $195.00K derived: sum of 3 quarters · filed 2023-03-15 | $679.00K 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $181.00K 10-Q · filed 2022-11-02 | $306.00K derived: sum of 2 quarters · filed 2022-11-02 | $790.00K 10-Q · filed 2022-11-02 | $934.00K derived: sum of 4 quarters · filed 2023-03-15 | ||
| 2022-06-30 | $125.00K 10-Q · filed 2022-08-11 | $609.00K 10-Q · filed 2022-08-11 | $753.00K derived: sum of 3 quarters · filed 2023-03-15 | $806.00K derived: sum of 4 quarters · filed 2023-03-15 | ||
| 2022-03-31 | $484.00K 10-Q · filed 2022-05-12 | $628.00K derived: sum of 2 quarters · filed 2023-03-15 | $681.00K derived: sum of 3 quarters · filed 2023-03-15 | $766.00K derived: sum of 4 quarters · filed 2023-03-15 | ||
| 2021-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $197.00K derived: sum of 2 quarters · filed 2023-03-15 | $282.00K derived: sum of 3 quarters · filed 2023-03-15 | $374.00K 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $53.00K 10-Q · filed 2022-11-02 | $138.00K derived: sum of 2 quarters · filed 2022-11-02 | $230.00K 10-Q · filed 2022-11-02 | $101.00K derived: sum of 4 quarters · filed 2022-11-02 | ||
| 2021-06-30 | $85.00K 10-Q · filed 2022-08-11 | $177.00K 10-Q · filed 2022-08-11 | $48.00K derived: sum of 3 quarters · filed 2022-08-11 | $162.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $92.00K 10-Q · filed 2022-05-12 | -$37.00K derived: sum of 2 quarters · filed 2022-05-12 | $77.00K derived: sum of 3 quarters · filed 2022-05-12 | $119.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$129.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | -$15.00K derived: sum of 2 quarters · filed 2022-03-11 | $27.00K derived: sum of 3 quarters · filed 2022-03-11 | $238.00K 10-K/A · filed 2022-03-11 | $8.50K 10-K · filed 2021-03-29 | |
| 2020-09-30 | $114.00K 10-Q · filed 2021-11-08 | $156.00K derived: sum of 2 quarters · filed 2021-11-08 | $367.00K 10-Q · filed 2021-11-08 | $680.00K derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $42.00K 10-Q · filed 2021-08-10 | $481.00K 10-Q · filed 2021-08-10 | $566.00K derived: sum of 3 quarters · filed 2021-08-10 | $566.00K derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $523.00K 10-Q · filed 2021-05-10 | $523.20K 10-Q · filed 2020-05-11 | $524.00K derived: sum of 2 quarters · filed 2021-05-10 | $524.00K derived: sum of 3 quarters · filed 2021-05-10 | $524.00K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $1.00K derived: sum of 2 quarters · filed 2020-11-06 | $1.00K derived: sum of 3 quarters · filed 2020-11-06 | $1.00K 10-K · filed 2020-03-09 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |